Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 805.31% ano a ano.
Sobreavaliada
O PE mais recente da empresa é 315.43, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 65.17M ações, uma redução de 9.44% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 34.18K ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.59.